Secor Capital Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Secor Capital Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-9,131	Closed	-$227K	–	615
2018 Q3	$227K	Sell	9,131 -9,692	-51%	-$264K	0.02%	392
2018 Q2	$517K	Buy	+18,823	New	+$566K	0.04%	381
2014 Q4	–	Sell	-22,175	Closed	-$429K	–	493
2014 Q3	$429K	Buy	+22,175	New	+$578K	0.24%	154

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

NCM

NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

Secor Capital Advisors's RVNC Position: Q4 2018 in Review

Secor Capital Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2018, closing a stake of 9,131 shares — an estimated $227K sold.

Secor Capital Advisors first reported a position in RVNC in Q3 2014 and held it in 3 quarters. The position peaked at $517K in Q2 2018. 101 funds tracked by Wall St. Rank hold RVNC as of Q4 2018.

Secor Capital Advisors reported no remaining Revance Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
Secor Capital Advisors sold 9,131 Revance Therapeutics, Inc. shares in Q4 2018, an estimated $227K.
Secor Capital Advisors first reported a position in Revance Therapeutics, Inc. in Q3 2014 and held it in 3 quarters.
Secor Capital Advisors's Revance Therapeutics, Inc. position peaked at $517K in Q2 2018.
101 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2018.

Based on Secor Capital Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.